Bassani-Sternberg Lab
Our focus
Our main goal is to identify clinically relevant cancer specific Human Leukocyte Antigen (HLA) ligands that will guide the development of personalized cancer immunotherapy using state of the art proteogenomics and mass-spectrometry (MS) approaches.
Our projects
- We develop proteogenomics and MS-based immunopeptidomics analytical and computational approaches to identify HLA ligands derived from tumor-associated proteins, mutated neoantigens, non-canonical ORFs and post translationally modified peptides.
- We have initiated fundamental discovery work to elucidate how tumor cells present antigens and what are the bases of tumor immunogenicity in mouse and human.
- We are investigating the differences between T cell inflamed and non-inflamed tumors in terms of antigen presentation and the antigenic landscape and how drugs modulate the immunopeptidome.
- We have established a continuous bioinformatics pipeline called NeoDisc enabling direct and personalized identification and prediction of neoantigens by combining genomic information derived from exome-seq analysis and transcriptomics data with measured immunopeptidomics data.
- We apply our discovery pipeline in the context of phase I clinical vaccine and adoptive T cell therapy trials at the CHUV to identify personalized neoantigens from patient tumor samples.
- Chong C., Müller M., Pak HuiSong, Harnett D., Huber F., Grun D., Leleu M., Auger A., Arnaud M., Stevenson B. J., Michaux J., Bilic I., Hirsekorn A., Calviello L., Simó-Riudalbas L., Planet E., Lubiński J., Bryśkiewicz M., Wiznerowicz M., Xenarios I., Zhang L., Trono D., Harari A., Ohler U., Coukos G., Bassani-Sternberg M*. (2020) Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nature Communications 11 (1). [10.1038/s41467-020-14968-9 ] *Corresponding author
- Racle J., Michaux J., Rockinger G.A., Arnaud M., Bobisse S., Chong C., Guillaume P., Coukos G., Harari A., Jandus C., Bassani-Sternberg M*., Gfeller D*. (2019) Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nature Biotechnology 37 (11) pp. 1283-1286. [10.1038/s41587-019-0289-6 ] *Co-corresponding author
- Bassani-Sternberg M.*, Digklia A., Huber F., Wagner D., Sempoux C., Stevenson B. J., Thierry A.-C., Michaux J., Pak HuiSong, Racle J., Boudousquie C., Balint K., Coukos G., Gfeller D., Martin Lluesma S., Harari A., Demartines N., Kandalaft L. E.* (2019) A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients. Frontiers in Immunology. 10 p. 1832. [10.3389/fimmu.2019.01832 ] [Full text] *Co-corresponding author.
Meet all the Bassani Group members.
|
Funding |
|
|
Affiliations |
|
|
Links |
|
.png)
